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In our search for antimicrobial compounds from Streptomyces spp. and rare actinomycetes of different ecological 
niches in Pakistan, an isolate Streptomyces sp. CRF17 isolated from a saline soil was investigated for its 
antimicrobial activity against different bacterial, fungal and algal test organisms. The biological screening 
revealed that the isolate exhibit potent antimicrobial activity against gram positive and gram negative bacterial 
test organisms along with minor antifungal and anti algal activity. The scale up fermentation of the isolate
Streptomyces sp. CRF17 as 20 liter lab fermenter (Biostat E) and extraction of the culture broth by ethyl acetate, 
acetone and methanol yielded 0.71 g crude extract. The subsequent isolation and purifications of the crude 
extract using several chromatographic techniques yielded one pure compound. The purified compound was 
identified by mass spectrometry (ESI and HRESI-MS) and by NMR analysis (1H and 13C NMR) as alborixin (1),
which was further, confirmed by comparison with the literature data. The morphological, biochemical and 
physiological characterization suggested that isolate CRF17 belongs to the genus Streptomyces. Further a partial 
16S rRNA gene sequence 1420 bp (gene bank accession number: EU294134) from the isolate CRF17 was 
determined and found to have high similarity 98 % with Streptomyces pulcher.
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Bacterial vaginosis (BV) is one of the most common gynecological disorder affecting women in reproductive 
age. This condition poses a significant health risk because it predisposes women to abnormal pregnancy, pelvic 
inflammatory disease and an increased risk of sexual transmitted infections, including HIV [1]. Although BV 
etiology remains unknown, it is characterized by a decrease in vaginal lactobacilli and a proliferation of 
anaerobes [1, 2]. Despite of the richness and diversity found into BV anaerobes, Gardnerella vaginalis is present 
in over 90% of the pathologic cases and several studies report its potential as the main etiological candidate [3, 4, 
5]. Current BV treatment is strictly based in antibiotic therapy resulting in an increased resistance of BV 
anaerobes, along with severe reduction of the healthy lactobacilli strains in the vaginal epithelium. Therefore, a 
more appropriate treatment is required, aiming to decrease G. vaginalis and also to promote the lactobacilli re-
colonization in BV patients [6]. Previous studies showed the potential of lactobacilli in preventing vaginal 
colonization by pathogens, and thus the development of infections, by different mechanisms including auto-
aggregation, co-aggregation with pathogenic microorganisms, and adhesion to epithelial cells and/or by 
producing some metabolites (such as lactic acid, hydrogen peroxide, bacteriocins and biosurfactants) that may 
act as growth inhibitors or anti-adhesive agents [7]. These probiotic properties have inspired new treatment 
strategies for vaginal infection. 
One alternative therapy for BV is the re-colonisation of vagina with lactobacilli species [6]. However, the major 
gap in this option resides in the choice of the most suitable lactobacillus species. Our goal was to evaluate the 
probiotic potential of intra and extracellular metabolites from a broad range of lactobacilli strains against several 
G. vaginalis strains. To accomplish our goal, we isolated 60 vaginal lactobacilli strains from healthy women and 
performed a screening by an agar spot test against 9 G. vaginalis strains (3 from culture collection and 6 clinical 
isolates from women with BV) in order to selected the most interesting probiotic candidates. We also included 
more than 30 culture collection lactobacilli strains. For the best candidates we determined the minimum 
inhibitory concentration (MIC) and identified the lactobacilli metabolites responsible for G. vaginalis growth 
inhibition.  
Our results showed that certain latobacilli metabolites were able to inhibit G. vaginalis growth. In spite of the 
detection of intracellular biosurfactants in some strains, they were unable to reduce G. vaginalis proliferation. On 
the other hand, extracellular products of some lactobacilli showed a significant effect on G. vaginalis growth. 
Overall, from the 90 lactobacilli strains tested, only 4 culture collection and 3 clinical isolate lactobacilli strains 
exhibited a broad probiotic activity against all the G. vaginalis strains tested. However, only culture collection 
strains were able to reduce G. vaginalis strains growth to 20-30% in MIC assays, illustrating an efficient 
probiotic activity by itself. Interestingly, none of these lactobacilli strains belong to the vaginal microflora, 
revealing a more pronounced probiotic activity than any of those vaginal isolate lactobacilli tested.  
Therefore, our data suggests the existence of non-vaginal lactobacilli strains possessing probiotic activity against 
numerous G. vaginalis strains, which may contribute for a new and more effective BV treatment than the 
currently used therapies.  
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